In Brief: Roche v. Organon Teknika
This article was originally published in The Gray Sheet
Executive Summary
Roche v. Organon Teknika: Organon Teknika's NASBA gene amplification technology used in two HIV tests available in Europe does not infringe Roche's European patent for polymerase chain reaction amplification technology, according to a Dec. 14 ruling by the President of the District Court in The Hague, the Netherlands. Rejecting Roche's request for an injunction of NASBA sales ("The Gray Sheet" Sept. 11, In Brief), the court stipulates that Roche must publicly announce the contents of the judgment and refrain from disseminating "further misleading information on the alleged infringement," Teknika says. Teknika adds that it has initiated pre-emptive legal action in the UK, France and Germany "to obtain declarations of non-infringement and is preparing such action in other countries." Roche says it will review the district court's findings before deciding whether it will appeal...
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.